Synthesis and evaluation of [18F]-FEAnGA as a PET Tracer for beta-glucuronidase activity.

To increase the therapeutic index of chemotherapeutic drugs, prodrugs have been investigated as anticancer agents, as they may present fewer cytotoxic side effects than conventional cytotoxic drugs, while therapeutic efficacy is maintained or even increased. Extracellular beta-glucuronidase (beta-GUS) in the tumors has been investigated as a target enzyme for prodrug therapy, as it can convert nontoxic prodrugs into cytostatic drugs. To optimize beta-GUS-based prodrug therapies, PET imaging could be a useful tool by providing information regarding the localization and quantification of beta-GUS. Here, we describe our first PET tracer for extracellular beta-GUS, [(18)F]-FEAnGA, which consists of a 2-[(18)F]fluoroethylamine ([(18)F]-FEA) group bound to a glucuronic acid via a self-immolative nitrophenyl spacer. [(18)F]-FEAnGA was synthesized by alkylation of its imidazole carbamate precursor with [(18)F]-FEA, followed by deprotection of the sugar moiety with NaOH in 10-20% overall radiochemical yield. [(18)F]-FEAnGA is about 10-fold more hydrophilic than the cleavage product [(18)F]-FEA, and it is stable in PBS and rat plasma for at least 3 h. In the presence of either Escherichia coli beta-GUS or bovine liver beta-GUS, in vitro cleavage of [(18)F]-FEAnGA with complete release of [(18)F]-FEA was observed within 30 min. C6 glioma cells incubated with the tracer and Escherichia coli beta-GUS or bovine liver beta-GUS showed a 4- and 1.5-fold higher uptake of radioactivity, respectively, as compared to control C6 cells without beta-GUS. Incubation of CT26 murine colon adenocarcinoma cells or the genetically engineered CT26mbetaGUS cells, which expressed membrane-anchored GUS on the outer cell membrane, with the tracer, resulted in a 3-fold higher uptake into GUS-expressing cells as compared to control cells. In a preliminary microPET study in mice bearing both CT26 and CT26mbetaGUS tumors, [(18)F]-FEAnGA exhibited a 2-fold higher retention of radioactivity in the tumor expressing beta-GUS than in the control tumor. [(18)F]-FEA did not show any difference in tracer uptake between tumors. These results suggest that [(18)F]-FEAnGA may be a suitable PET tracer for evaluation of beta-GUS activity, since it is specifically cleaved by beta-GUS and the released [(18)F]-FEA remains attached to targeted cells.

[1]  H. Haisma,et al.  Tumor-specific activation of prodrugs: is there a role for nuclear medicine? , 2008, Nuclear medicine communications.

[2]  J. George.  Elevated serum beta-glucuronidase reflects hepatic lysosomal fragility following toxic liver injury in rats. , 2008, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[3]  J. Chern,et al.  Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. , 2008, Journal of medicinal chemistry.

[4]  L. Mortelmans,et al.  Synthesis and evaluation of 18F- and 11C-labeled phenyl-galactopyranosides as potential probes for in vivo visualization of LacZ gene expression using positron emission tomography. , 2008, Bioconjugate chemistry.

[5]  J-Y Wang,et al.  Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored β-glucuronidase , 2007, Gene Therapy.

[6]  F. Zihnioglu,et al.  Scintigraphic imaging with a peptide glucuronide in rabbits: 99mTc- exorphin C glucuronide. , 2007, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[7]  E. Medine,et al.  Synthesis of an estradiol glucuronide derivative and investigation of its radiopharmaceutical potential. , 2006, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[8]  S. Papot,et al.  Synthesis and Evaluation of p-Nitrophenylβ-D-Glucopyranosiduronic Analogues as New Triggers for β-Glucuronidase Mediated Prodrug Mono- Therapy , 2005 .

[9]  A. Pegg,et al.  Beta-glucuronidase-cleavable prodrugs of O6-benzylguanine and O6-benzyl-2'-deoxyguanosine. , 2005, Journal of medicinal chemistry.

[10]  I. Tranoy-Opalinski,et al.  A new linker for glucuronylated anticancer prodrugs. , 2004, Bioorganic & medicinal chemistry.

[11]  W. Denny,et al.  Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy) , 2003, Journal of biomedicine & biotechnology.

[12]  P. Wang,et al.  Glucuronides in anti-cancer therapy. , 2003, Current medicinal chemistry. Anti-cancer agents.

[13]  A. McEwan,et al.  [99mTc]Technetium labelled PnAo-azomycin glucuronides: a novel class of imaging markers of tissue hypoxia. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[14]  H. W. Scheeren,et al.  Beta-glucuronidase-mediated drug release. , 2002, Current pharmaceutical design.

[15]  J. Florent,et al.  Design of selectively activated anticancer prodrugs: elimination and cyclization strategies. , 2002, Current medicinal chemistry. Anti-cancer agents.

[16]  S. Osman,et al.  Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. , 2001, Current pharmaceutical design.

[17]  H. W. Scheeren,et al.  Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. , 2001, Current medicinal chemistry.

[18]  H. Kroemer,et al.  Expression and function of β-glucuronidase in pancreatic cancer: potential role in drug targeting , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[19]  A. Gutman,et al.  Synthesis of morphine 6-α-d-glucuronide , 2000 .

[20]  J. Drewe,et al.  Modulation of morphine-6-glucuronide penetration into the brain by P-glycoprotein. , 1998, International journal of clinical pharmacology and therapeutics.

[21]  M. Rosenblum,et al.  Intensely cytotoxic anthracycline prodrugs: glucuronides. , 1997, Journal of medicinal chemistry.

[22]  T. Tewson.  Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia. , 1997, Nuclear medicine and biology.

[23]  H K Kroemer,et al.  Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: consequences for drug metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[24]  H. Pinedo,et al.  Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy. , 1996, Biochemical pharmacology.

[25]  J. Drewe,et al.  Evidence for P‐glycoprotein‐modulated penetration of morphine‐6‐glucuronide into brain capillary endothelium , 1996, British journal of pharmacology.

[26]  K. Bosslet,et al.  Tumor-selective prodrug activation by fusion protein-mediated catalysis. , 1994, Cancer research.

[27]  J. Tomašić,et al.  The kinetics of hydrolysis of synthetic glucuronic esters and glucuronic ethers by bovine liver and Escherichia coli beta-glucuronidase. , 1973, The Biochemical journal.

[28]  R. Weissleder,et al.  A self-immolative reporter for beta-galactosidase sensing. , 2007, Chembiochem : a European journal of chemical biology.

[29]  T. Cheng,et al.  Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. , 2007, Cancer gene therapy.

[30]  S. Chittaboina,et al.  A Facile Route for the Regioselective Deacetylation of Peracetylated Carbohydrates at Anomeric Position , 2006 .

[31]  T. Meade,et al.  A gadolinium chelate for detection of beta-glucuronidase: a self-immolative approach. , 2005, Journal of the American Chemical Society.

[32]  A. Stachulski,et al.  The synthesis of O-glucuronides. , 1998, Natural product reports.

[33]  I. Tannock,et al.  Lysosomes, lysosomal enzymes, and cancer. , 1993, Advances in cancer research.